Physician profile

Salman A Arain

Interventional Cardiology · Houston, TX

NPI 1245285352

$108,140.64

in general payments reported to CMS, 2019-2025

32 companies · $29K in 2025

The $29K reported for 2025 was more than what 95% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).

See the full distribution for Interventional Cardiology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$42,437.50
Food and Beverage$10,304.16
Consulting Fee$7,500.00
Travel and Lodging$6,131.24
Honoraria$6,000.00
Education$10.17

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $43,080.76 2019-2025 General - Vascular Access, General - Balloon Catheters, Avvigo Guidance System
Canon Medical Systems USA, INC. $17,041.76 2020-2025 Interventional Angiography System, General Non-Equipment, Ct Scanner
Arrow International, INC. $15,472.92 2019-2024 Manta
Teleflex LLC $13,077.88 2019-2025 Guideliner, Turnpike, Manta
Abbott Laboratories $7,259.20 2019-2025 Amplatzer Amulet, Dragonfly Opstar, Diamondback Coronary
Abiomed $5,103.84 2019-2024 Impella
Shockwave Medical, INC $2,363.17 2024-2025 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Asahi Intecc USA, INC. $638.43 2023-2025 Peripheral Vascular, Asahi Ptca Guide Wire, Asahi Peripheral Vascular Wires
Amgen INC. $410.70 2022-2024 Repatha
Biotronik INC. $401.60 2019-2024 Orsiro Mission
Medtronic Vascular, INC. $353.03 2019
Shimadzu Precision Instruments, INC. $346.81 2019
Edwards Lifesciences Corporation $317.68 2024-2025 Evoque
Medtronic, INC. $283.45 2021-2022
Boehringer Ingelheim Pharmaceuticals, INC. $248.53 2021-2024 Jardiance
Show all 32 companies
CompanyGeneral paymentsYearsTop products
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $242.97 2019-2021
Astrazeneca Pharmaceuticals LP $213.31 2019-2020
Heartflow, INC. $199.87 2024
Pfizer INC. $198.30 2023-2025
Bard Peripheral Vascular, INC. $154.05 2021-2022
Inari Medical, INC. $152.42 2022
Novartis Pharmaceuticals Corporation $119.80 2021-2025
Philips North America LLC $108.11 2023
Cardiovascular Systems INC. $103.62 2019-2020
Teleflex Medical Canada INC. $94.24 2023
E.R. Squibb & Sons, L.L.C. $35.11 2024-2025 Eliquis, Camzyos
Arrow Interventional, INC. $30.32 2019
Imperative Care, INC $27.80 2025 Symphony Catheter
Scpharmaceuticals INC. $18.56 2025
Siemens Medical Solutions USA, INC. $17.80 2020
Cagent Vascular INC $12.60 2025 Serrantor
Osprey Medical INC $12.00 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Salman A Arain

$108,140.64

in general payments reported 2019-2025

Years
2019-2025
Top company
Boston Scientific Corporation
Context
The $29K reported for 2025 was more than what 95% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).

https://glasscript.com/doctor/282826/salman-a-arain

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.